The drug didn’t affect blood sugar or fat levels in the blood, so its benefits aren’t due to improving how the body handles sugar or fat.
Scientific Claim
In apolipoprotein E-deficient mice on a high-fat high-cholesterol diet, MPE-298 treatment is associated with no significant change in plasma free fatty acid or glycemia levels compared to vehicle controls, indicating that glucose and lipid metabolism are not primary mediators of its effects.
Original Statement
“In addition, no change in glycemia nor free fatty acid levels was observed in azapeptide-treated mice fed a HFHC diet at 20 weeks of age, compared to that of vehicle-treated mice (Supplementary Figures S6A, B).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim accurately reflects the non-significant findings using appropriate associative language, consistent with study limitations.
More Accurate Statement
“In apolipoprotein E-deficient mice on a high-fat high-cholesterol diet, MPE-298 treatment is associated with no significant change in plasma free fatty acid or glycemia levels compared to vehicle controls.”
Evidence from Studies
Supporting (0)
Contradicting (1)
The study didn’t measure blood sugar or fat levels, so we can’t say whether MPE-298 affects them or not—the claim is making a statement that the study never tested.